中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2013年
2期
43-45
,共3页
潘三葱%秦中胜%张卫玲%韩麦丰%崔花花
潘三蔥%秦中勝%張衛玲%韓麥豐%崔花花
반삼총%진중성%장위령%한맥봉%최화화
N末端B型利钠肽原%慢性心力衰竭%诊断%预后
N末耑B型利鈉肽原%慢性心力衰竭%診斷%預後
N말단B형리납태원%만성심력쇠갈%진단%예후
N-terminal pro-brain natiuretic peptide%Chronic heart failure%Diagnosis%Prognosis
目的 探讨N末端B型利钠肽原(NT-proBNP)对慢性心力衰竭(CHF)诊断和预后判断的价值.方法 202例CHF患者初次入院后根据纽约心脏病协会(NYHA)心功能进行分级,行超声心动图检查,测定左心室射血分数(LVEF),入院后初始和治疗14 d后两次测定血浆NT-proBNP,并设20例健康人作为对照.所有CHF患者至少随访1年.对相关数据作统计学处理.结果 CHF患者血浆NT-proBNP中位数显著高于正常对照组,分别为2791 pg/ml和40 pg/ml(P＜0.01).随着NYHA心功能级别的升高NT-proBNP浓度升高,差异有统计学意义(P＜0.05).随着LVEF值的下降NT-proBNP浓度有升高趋势,但差异无统计学意义(P＞0.05).出院时NT-proBNP持续≥5000 pg/ml组年病死率为14.9％,NT-proBNP＜ 5000 pg/ml组年病死率为1.3％,差异有统计学意义(P＜0.01).结论 N末端B型利钠肽原(NT-proBNP)是诊断慢性心力衰竭(CHF)的可靠方法,与NYHA心功能分级密切相关,并对预后判断具有重要价值.
目的 探討N末耑B型利鈉肽原(NT-proBNP)對慢性心力衰竭(CHF)診斷和預後判斷的價值.方法 202例CHF患者初次入院後根據紐約心髒病協會(NYHA)心功能進行分級,行超聲心動圖檢查,測定左心室射血分數(LVEF),入院後初始和治療14 d後兩次測定血漿NT-proBNP,併設20例健康人作為對照.所有CHF患者至少隨訪1年.對相關數據作統計學處理.結果 CHF患者血漿NT-proBNP中位數顯著高于正常對照組,分彆為2791 pg/ml和40 pg/ml(P＜0.01).隨著NYHA心功能級彆的升高NT-proBNP濃度升高,差異有統計學意義(P＜0.05).隨著LVEF值的下降NT-proBNP濃度有升高趨勢,但差異無統計學意義(P＞0.05).齣院時NT-proBNP持續≥5000 pg/ml組年病死率為14.9％,NT-proBNP＜ 5000 pg/ml組年病死率為1.3％,差異有統計學意義(P＜0.01).結論 N末耑B型利鈉肽原(NT-proBNP)是診斷慢性心力衰竭(CHF)的可靠方法,與NYHA心功能分級密切相關,併對預後判斷具有重要價值.
목적 탐토N말단B형리납태원(NT-proBNP)대만성심력쇠갈(CHF)진단화예후판단적개치.방법 202례CHF환자초차입원후근거뉴약심장병협회(NYHA)심공능진행분급,행초성심동도검사,측정좌심실사혈분수(LVEF),입원후초시화치료14 d후량차측정혈장NT-proBNP,병설20례건강인작위대조.소유CHF환자지소수방1년.대상관수거작통계학처리.결과 CHF환자혈장NT-proBNP중위수현저고우정상대조조,분별위2791 pg/ml화40 pg/ml(P＜0.01).수착NYHA심공능급별적승고NT-proBNP농도승고,차이유통계학의의(P＜0.05).수착LVEF치적하강NT-proBNP농도유승고추세,단차이무통계학의의(P＞0.05).출원시NT-proBNP지속≥5000 pg/ml조년병사솔위14.9％,NT-proBNP＜ 5000 pg/ml조년병사솔위1.3％,차이유통계학의의(P＜0.01).결론 N말단B형리납태원(NT-proBNP)시진단만성심력쇠갈(CHF)적가고방법,여NYHA심공능분급밀절상관,병대예후판단구유중요개치.
Objective To observe the diagnostic and prognostic value of N-terminal pro-brain natiuretic peptide(NT-proBNP) for patients with chronic heart failure(CHF).Methods A total of 202 patients diagnosed with chronic heart failure were checked with echocardiography,were divided into Ⅱ to Ⅳ NYHA class,measured for plasma NT-proBNP on admission and on 14 days after conventional therapy.Twenty healthy people were measured for plasma NT-proBNP.Patients with CHF were followed for at least 1 year.Results The median NT-proBNP level was significantly higher in CHF group (2791 pg/ml) than in healthy group(40 pg/ml,P ＜ 0.01).The median NT-proBNP level was significantly higher in NYHA class Ⅳ than in NYHA class Ⅲ and in NYHA class Ⅱ (P ＜ 0.05).One year mortality of patients those median NT-proBNP level ≥5000 pg/ml at discharge was significantly higher(14.9％) than that of median NT-proBNP level ＜ 5000 pg/ml at discharge(1.3％,P ＜ 0.01).Conclusions Plasma NT-proBNP served as a parameter for diagnosing chronic decompensate heart failure and a strong predictor of one year mortality.
